Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$7.66 0.25 (3.37%)
2/9/2010 4:00 PM

The Medicines Company (MDCO)

CAPS Rating:
***

A pharmaceutical company provides innovative, cost effective acute care hospital products to the worldwide hospital marketplace.

X

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating MDCO

Add Stock to Watchlist

What the Community Thinks

Total Members

95 Outperforms
16 Underperforms
 

All-Stars

31 Outperforms
3 Underperforms
 

Wall Street

3 Outperforms
2 Underperforms
 

Members bullish on MDCO are also bullish on:

Members bearish on MDCO are also bearish on:

Ticker Tags

Value (1901), Healthcare (711), Micro Cap (4701), Defensive (1457), Pharmaceuticals (149)
Suggest a tag

The Medicines Company At A Glance

Current Price: $7.66
Last Trade Time: 2/9/2010 4:00 PM
Open: $0.00
Previous Close: $7.41
Daily Range: $7.38 - $7.67
52-Week Range: $6.15 - $14.51
Volume: 488,027
Market Cap: $404.99M
P/E Ratio: 9.88
Compare Our Special Broker Offers!

Stock Trends

MDCO VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

The Medicines Company (MDCO)

Avatar TSIF (98.89) Submitted: 5/12/09 2:46 PM

The Medicine Company, winning name, great pitch, "cost effective acute care"!. How could it lose! Overall for a pharmaceutical company Medicines has a decent and increasing revenue stream from Angiomax and several other products. From the company profile Angiomax is " an intravenous direct thrombi...More

Replies: 1 | Reply | Permalink

Top Bear Pitch

Recs

1

The Medicines Company (MDCO)

Avatar agard43 (< 20) Submitted: 3/22/07 10:31 PM

TheStreet.com: "There still seems to be a lot of hope built into the stock price. As Morgan Stanley analyst Stephen Herr wrote this week, "if the patent life is not extended, this stock looks broadly overvalued."

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 11 :   1 2 3 Next »

Show Pitch Replies

Recs

0

 (MDCO)

Avatar Magnet0 (49.57) Submitted: 5/13/09 5:50 PM : Outperform Start Price: $7.22 MDCO Score: -16.01

quality company, took a fatty nose dive

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (MDCO)

Avatar TSIF (98.89) Submitted: 5/12/09 2:46 PM : Outperform Start Price: $11.14 MDCO Score: -50.66

The Medicine Company, winning name, great pitch, "cost effective acute care"!. How could it lose! Overall for a pharmaceutical company Medicines has a decent and increasing revenue stream from Angiomax and several other products. From the company profile Angiomax is " an intravenous direct thrombin inhibitor for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty". Wow, I don't know what it means, but it must be good! Yes, patents are short, which appears to be keeping the price down, but it has other drugs in the "blood arena" and we all need healthy blood! They will need to watch their backs, but no debt, cash flow, well respected products and a good distribution system and I'd rather have my money in a company like this than an auto parts or a bank, especially if I need to go to the hospital to have my thromin fixed.

Report this Post Replies: 1 | Reply | Permalink

Recs

1

 (MDCO)

Avatar zzlangerhans (99.64) Submitted: 2/20/09 1:07 PM : Outperform Start Price: $12.61 MDCO Score: -82.67

It's not clear to me why Medicines has fallen so far despite a relatively stable financial picture. Angiomax revenues have been increasing and generics will not be available before 2010 at the earliest. That gives Medicines time to grow Cleviprex revenues and develop their pipeline. I'm not really a bull here but this company has the tools to survive and will likely be one to rebound in the short term when the market stabilizes, given no major negative catalysts.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MDCO)

Avatar escarzamd (< 20) Submitted: 5/31/08 2:26 PM : Outperform Start Price: $18.25 MDCO Score: -37.55

Hearing good things from cardiologists about Angiomax. recent support from journals. Could be a combo w/BMY for cath patients. No debt on board, so if this drug hits.......the stock could go out of the yard.

Report this Post Replies: 1 | Reply | Permalink

Recs

1

 (MDCO)

Avatar popsstocs (< 20) Submitted: 9/08/07 3:39 PM : Outperform Start Price: $16.47 MDCO Score: -30.52

I have made some good profits off this CO.I guess it makes all that money from selling all those expensive medications,but what ever,It does me good and I played it again,and its already on its way to do ole pops right again.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 11 :   1 2 3 Next »

Wall Street

Results 1 - 5 of 5  

picks per page. CHANGE

Top
Pick		Member NameMember RatingStart
Date		CallTime FrameStart
Price		Stock
Gain		S&P
Gain		ScorePitch
TrackWedbush 66.12 09/15/09 Underperform NS $11.08-30.87%+2.16%+33.03
TrackCitigroup 85.92 02/14/08 Outperform NS $21.23-63.92%-18.41%-45.51
TrackJMP 71.98 04/30/07 Outperform NS $23.13-66.88%-24.26%-42.63
TrackBroadpoint.AmTech 76.97 10/26/06 Outperform NS $24.65-68.92%-17.95%-50.97
TrackJimCramer < 20 03/13/06 Underperform 3W $21.40-64.21%-10.72%+53.49

Results 1 - 5 of 5  

X

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD01 843ms